- Home
- VRAX vs BKYI Comparison
VRAX vs BKYI Comparison
Compare VRAX & BKYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- BKYI
- Stock Information
- Founded
- VRAX 2013
- BKYI 1993
- Country
- VRAX United Kingdom
- BKYI United States
- Employees
- VRAX N/A
- BKYI N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BKYI Computer Software: Prepackaged Software
- Sector
- VRAX Health Care
- BKYI Technology
- Exchange
- VRAX Nasdaq
- BKYI Nasdaq
- Market Cap
- VRAX 4.4M
- BKYI 4.8M
- IPO Year
- VRAX 2022
- BKYI 1997
- Fundamental
- Price
- VRAX $0.55
- BKYI $0.73
- Analyst Decision
- VRAX Strong Buy
- BKYI
- Analyst Count
- VRAX 1
- BKYI 0
- Target Price
- VRAX $3.00
- BKYI N/A
- AVG Volume (30 Days)
- VRAX 1.4M
- BKYI 127.4K
- Earning Date
- VRAX 01-01-0001
- BKYI 08-13-2025
- Dividend Yield
- VRAX N/A
- BKYI N/A
- EPS Growth
- VRAX N/A
- BKYI N/A
- EPS
- VRAX N/A
- BKYI N/A
- Revenue
- VRAX $6,331.00
- BKYI $6,911,148.00
- Revenue This Year
- VRAX $217,274.83
- BKYI $7.45
- Revenue Next Year
- VRAX N/A
- BKYI $23.29
- P/E Ratio
- VRAX N/A
- BKYI N/A
- Revenue Growth
- VRAX N/A
- BKYI N/A
- 52 Week Low
- VRAX $0.52
- BKYI $0.52
- 52 Week High
- VRAX $4.44
- BKYI $3.68
- Technical
- Relative Strength Index (RSI)
- VRAX 29.17
- BKYI 40.02
- Support Level
- VRAX $0.52
- BKYI $0.71
- Resistance Level
- VRAX $0.65
- BKYI $0.77
- Average True Range (ATR)
- VRAX 0.05
- BKYI 0.03
- MACD
- VRAX -0.01
- BKYI 0.00
- Stochastic Oscillator
- VRAX 10.32
- BKYI 22.33
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.